ZURA vs. CHRS, IPHA, AGEN, ABOS, CMPX, GLUE, IVVD, INMB, MGX, and ADAP
Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Coherus BioSciences (CHRS), Innate Pharma (IPHA), Agenus (AGEN), Acumen Pharmaceuticals (ABOS), Compass Therapeutics (CMPX), Monte Rosa Therapeutics (GLUE), Invivyd (IVVD), INmune Bio (INMB), Metagenomi (MGX), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "biological products, except diagnostic" industry.
Zura Bio (NASDAQ:ZURA) and Coherus BioSciences (NASDAQ:CHRS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends, earnings and community ranking.
61.1% of Zura Bio shares are held by institutional investors. Comparatively, 72.8% of Coherus BioSciences shares are held by institutional investors. 15.8% of Zura Bio shares are held by company insiders. Comparatively, 7.6% of Coherus BioSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Zura Bio has a net margin of 0.00% compared to Coherus BioSciences' net margin of -19.64%. Coherus BioSciences' return on equity of 0.00% beat Zura Bio's return on equity.
Zura Bio presently has a consensus target price of $18.83, suggesting a potential upside of 234.52%. Coherus BioSciences has a consensus target price of $8.83, suggesting a potential upside of 328.80%. Given Coherus BioSciences' higher possible upside, analysts plainly believe Coherus BioSciences is more favorable than Zura Bio.
Zura Bio has higher earnings, but lower revenue than Coherus BioSciences.
Coherus BioSciences received 425 more outperform votes than Zura Bio when rated by MarketBeat users. However, 100.00% of users gave Zura Bio an outperform vote while only 65.07% of users gave Coherus BioSciences an outperform vote.
Zura Bio has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500. Comparatively, Coherus BioSciences has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
In the previous week, Coherus BioSciences had 2 more articles in the media than Zura Bio. MarketBeat recorded 4 mentions for Coherus BioSciences and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.00 equaled Coherus BioSciences'average media sentiment score.
Summary
Coherus BioSciences beats Zura Bio on 8 of the 14 factors compared between the two stocks.
Get Zura Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for ZURA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Zura Bio Competitors List
Related Companies and Tools
